220 related articles for article (PubMed ID: 37133467)
21. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment?
Hoseyni H; Xu Y; Zhou H
J Clin Pharmacol; 2018 Jul; 58(7):864-876. PubMed ID: 29462502
[TBL] [Abstract][Full Text] [Related]
22. A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
Cheifetz AS; Abreu MT; Afif W; Cross RK; Dubinsky MC; Loftus EV; Osterman MT; Saroufim A; Siegel CA; Yarur AJ; Melmed GY; Papamichael K
Am J Gastroenterol; 2021 Oct; 116(10):2014-2025. PubMed ID: 34388143
[TBL] [Abstract][Full Text] [Related]
23. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
Dutt K; Vasudevan A
Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399538
[No Abstract] [Full Text] [Related]
25. Optimization of biologics to reduce treatment failure in inflammatory bowel diseases.
Bourchany A; Gilletta De Saint-Joseph C; Breton A; Barreau F; Mas E
Curr Opin Pharmacol; 2020 Oct; 54():51-58. PubMed ID: 32947075
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?
Wu JF
Gut Liver; 2022 Jul; 16(4):515-524. PubMed ID: 34670875
[TBL] [Abstract][Full Text] [Related]
27. Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?
Anjie SI; Hulshoff MS; D'Haens G
Expert Opin Biol Ther; 2023 Apr; 23(4):341-351. PubMed ID: 37010030
[TBL] [Abstract][Full Text] [Related]
28. Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?
Abdalla T; Lowes MA; Kaur N; Micheletti RG; Steinhart AH; Alavi A
Am J Clin Dermatol; 2021 Mar; 22(2):139-147. PubMed ID: 33398848
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring.
Albader F; Golovics PA; Gonczi L; Bessissow T; Afif W; Lakatos PL
World J Gastroenterol; 2021 Oct; 27(37):6231-6247. PubMed ID: 34712029
[TBL] [Abstract][Full Text] [Related]
30. Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
Roblin X; Riviere P; Flamant M; Veyrard P; Poullenot F; Paul S; Laharie D
Inflamm Bowel Dis; 2018 Aug; 24(9):1904-1909. PubMed ID: 29726958
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy.
Shanmugam VK; Mulani S; McNish S; Harris S; Buescher T; Amdur R
Int J Dermatol; 2018 Jan; 57(1):62-69. PubMed ID: 29130482
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.
Mitrev N; Leong RW
Expert Opin Drug Saf; 2017 Mar; 16(3):303-317. PubMed ID: 27922765
[TBL] [Abstract][Full Text] [Related]
33. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.
Steenholdt C; Bendtzen K; Brynskov J; Ainsworth MA
Inflamm Bowel Dis; 2016 Aug; 22(8):1999-2015. PubMed ID: 27135483
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis: The efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease.
Sethi S; Dias S; Kumar A; Blackwell J; Brookes MJ; Segal JP
Aliment Pharmacol Ther; 2023 Jun; 57(12):1362-1374. PubMed ID: 36495020
[TBL] [Abstract][Full Text] [Related]
35. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.
Tikhonova IA; Yang H; Bello S; Salmon A; Robinson S; Hemami MR; Dodman S; Kharechko A; Haigh RC; Jani M; McDonald TJ; Hoyle M
Health Technol Assess; 2021 Feb; 25(8):1-248. PubMed ID: 33555998
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Drug Monitoring in Pediatric IBD: Current Application and Future Perspectives.
Lega S; Bramuzzo M; Dubinsky MC
Curr Med Chem; 2018; 25(24):2840-2854. PubMed ID: 28901267
[TBL] [Abstract][Full Text] [Related]
37. An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease.
Patel RN; Nigam GB; Jatale RG; Desai D; Makharia G; Ahuja V; Limdi JK
Indian J Gastroenterol; 2020 Apr; 39(2):176-185. PubMed ID: 32483692
[TBL] [Abstract][Full Text] [Related]
38. Interventions for hidradenitis suppurativa.
Ingram JR; Woo PN; Chua SL; Ormerod AD; Desai N; Kai AC; Hood K; Burton T; Kerdel F; Garner SE; Piguet V
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010081. PubMed ID: 26443004
[TBL] [Abstract][Full Text] [Related]
39. Advantages of Proactive Therapeutic Drug Monitoring in a Prospective Cohort of Children With Inflammatory Bowel Disease Treated With Anti-Tumour Necrosis Factor.
Gasparetto M; Burgess N; Naik S; Studart D; Kadir A; Croft N; Sanderson I; Deb P
J Pediatr Gastroenterol Nutr; 2022 Apr; 74(4):484-489. PubMed ID: 35129158
[TBL] [Abstract][Full Text] [Related]
40. A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy.
Yao J; Jiang X; You JHS
Inflamm Bowel Dis; 2021 Jan; 27(2):275-282. PubMed ID: 32311018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
